Aggravation of discoid lupus erythematosus in a patient with psoriasis and psoriatic arthritis during treatment of secukinumab: A case report and review of literature
Journal
Lupus
Journal Volume
31
Journal Issue
7
Pages
891
Date Issued
2022-06
Author(s)
Hsieh, Chang-Yu
Abstract
The coexistence of psoriasis and cutaneous lupus erythematosus (LE) is uncommon. Treatment for concomitant psoriasis and LE is challenging because some valid treatments for LE such as hydroxychloroquine and systemic corticosteroid are known to aggravate psoriasis. Th17 pathway is shared by these two disease entities. Thus, biologics targeting Th17 pathway, including ustekinumab and secukinumab, have been successfully used in the treatment of patients with concomitant psoriasis and LE.
Subjects
Th17; discoid lupus erythematosus; psoriasis; psoriatic arthritis; secukinumab
SDGs
Publisher
SAGE PUBLICATIONS LTD
Type
review